AstraZeneca and Alexion’s generalized myasthenia gravis treatment Klygefa (gefurolimab) received FDA approval as a once-weekly, self-administered therapy for patients with anti-acetylcholine receptor antibodies. The decision places the drug into a crowded gMG landscape where clinical adoption will depend on real-world tolerability, administration practicality, and comparative efficacy. For companies and clinicians, the key near-term questions are how Klygefa performs across symptom burdens and how it stacks against existing options including complement inhibitors and FcRn antagonists. The approval also sets expectations for post-marketing evidence generation in the FDA-approved population. The wider impact is clear for biotech market positioning: regulatory clearance can rapidly reframe treatment algorithms and reshape competitive intensity around neuromuscular immunology.
Get the Daily Brief